CRISPR Therapeutics Q1 Earnings and Sales Miss Estimates, Stock Tanks

CRISPR Therapeutics (CRSP) reported first-quarter 2025 loss of $1.58 per share, which was wider than the Zacks Consensus Estimate of a loss of$1.27 per share. In the year-ago period, the company had recorded a loss of $1.43 per share. Total revenues, comprising only grant revenues, amounted to$0.86 million in the quarter, which significantly missed the Zacks Consensus Estimate of $5 million. In the year-ago period, the company recorded total revenues of$0.5 million, which also comprised grant revenues. S ...